Genomics Launches Mystra AI Platform to Accelerate Drug Target Discovery Using Human Genetics Data

Advertisement

The company said the platform is already being used by major pharmaceutical organizations and emerging biotechnology firms.

London-based techbio company Genomics has launched Mystra AI, a conversational artificial intelligence platform designed to support drug target discovery and validation using large-scale human genetics data. The company said the platform is already being used by major pharmaceutical organizations and emerging biotechnology firms.

The launch comes as the pharmaceutical industry continues to face high research and development (R&D) failure rates. According to Genomics, approximately 95% of drug candidates entering clinical trials fail, contributing to average development costs exceeding $2.3 billion per approved medicine. The company stated that drug targets supported by human genetic evidence are 2.6 times more likely to succeed in clinical trials.

Mystra AI is built on what Genomics describes as the world's largest and most diverse genotype-phenotype database. Over the past decade, the company has compiled and standardized data from more than 45,000 genome-wide association studies (GWAS), encompassing trillions of data points. Using this dataset, Genomics reports having identified more than 100 potential drug targets across conditions including cancer, cardiovascular disease, and diabetes.

The platform uses agentic AI workflows and a conversational interface that allows scientists to query complex genetic datasets using natural language. Genomics said each output is supported by underlying data, visualizations, and genetic evidence, enabling users to review and verify findings.

According to the company, Mystra AI is intended for scientists working across Research & Development as well as Business Development and Licensing functions. The platform is designed to help users assess drug target efficacy and safety, investigate disease mechanisms, identify new therapeutic opportunities, and evaluate existing drug candidates.

Professor Sir Peter Donnelly, CEO and co-founder of Genomics, said the platform aims to simplify access to genetic insights for scientists involved in drug discovery and development. David Thornton, President of Genomics, noted that integrating large-scale human association data into AI-driven workflows could help researchers identify new treatment opportunities more efficiently.

Several organizations highlighted their use of the platform. Novo Nordisk said it partnered with Genomics after exploring internal alternatives, while BridgeBio Pharma reported improvements in genomics data analysis workflows. Relation Therapeutics stated that Mystra AI has supported its research teams in evaluating biological insights more rapidly.

Genomics is offering Mystra AI through self-service software subscriptions, partially managed deployments that integrate proprietary datasets, and fully managed collaborations with its statistical genetics research team.

Stay tuned for more such updates on Digital Health News